Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K220088
    Date Cleared
    2023-03-30

    (443 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Powder Free Nitrile Examination Gloves, Non-Sterile, and tested for Use with Chemotherapy Drugs and Fentanyl Citrate is a patient medical exam gloves which is disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between examiner and patient. The glove was tested for use with Chemotherapy Drugs and Fentanyl Citrate as per ASTM-D6978-05 Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

    Device Description

    Powder Free Nitrile Examination Gloves, Non-Sterile, and Tested for Juse with Chemotherapy Drugs and Fentanyl Citrate meets all the requirements of ASTM D6319-10 Standard Specification for Nitrile Examination Gloves for Medical Application. The principal operation and mechanism of this device is to prevent contamination between patient and examiner and this principle is achieved through testing of barrier, physical properties and other testing stated in the performance data. This device is for over-the-counter single use. It is an ambidextrous, light blue colour device with wide range of sizes, i.e (XS, S, M, L and XL). It is designated for single use only.

    AI/ML Overview

    The document describes the acceptance criteria and performance data for the "Powder Free Nitrile Examination Glove, Non-Sterile, and Tested for Use with Chemotherapy Drugs and Fentanyl Citrate". This is a medical device, and the evaluation focuses on its physical properties, chemical permeation resistance, and biocompatibility.

    Here's the breakdown of the requested information:

    1. Table of Acceptance Criteria and Reported Device Performance

    Characteristic / TestStandardAcceptance CriteriaReported Device PerformanceOutcome
    Physical Properties
    Length (Physical Dimension)ASTM D6319-10Min 240mmMin 240mmPassed
    Thickness Palm & Finger (Physical Dimension)ASTM D6319-10Min 0.05mmMin 0.05mmPassed
    Width by sizes (XS, S, M, L, XL) (Physical Dimension)ASTM D6319-10XS - 70mm, S - 80mm, M - 95mm, L - 110mm, XL - 120mm (Tolerance: ± 10mm)XS - 70mm, S - 80mm, M - 95mm, L - 110mm, XL - 120mm (Tolerance: ± 10mm)Passed
    Tensile Strength Before Aged (Physical Properties)ASTM D6319-10Min: 14MPaMin: 14MPaPassed
    Tensile Strength After Aged (Physical Properties)ASTM D6319-10Min: 14MPaMin: 14MPaPassed
    Ultimate Elongation Before Aged (Physical Properties)ASTM D6319-10Min 500%Min 500%Passed
    Ultimate Elongation After Aged (Physical Properties)ASTM D6319-10Min 400%Min 400%Passed
    Powder Content (Powder Residual)ASTM D6124-06(2017)Powder Amount: < 2mgPowder Amount: < 2mgPassed
    Freedom from Holes (Watertight @1000ml)ASTM D5151-19AQL 2.5AQL 2.5Passed
    Biocompatibility
    Irritation and delayed-type hypersensitivityISO 10993-10:2010No Skin sensitization and irritationNo skin sensitization and irritationPassed
    CytotoxicityISO 10993-5:2009No Cytotoxicity ReactionExhibits severe cytotoxicity reactivity at 100%, 66% extract concentrations. No cytotoxicity at 44%, 30%, 20%, 15% extract concentrations. (Subject device: undiluted, 1:2 and 1:4 dilution is cytotoxicity and the dilution 1:8 and 1:16 and 1:32 is non-cytotoxic.)Failed (based on acceptance criteria interpreted as "no cytotoxicity reaction" at any concentration) - Note: The document states "Cytotoxicity reaction, Failed" for the subject device.
    Acute Systemic toxicityISO 10993-11:2017No adverse biological reactionNo adverse biological reactionPassed
    Chemical Permeation (Chemotherapy Drugs)ASTM D6978Minimum Breakthrough Detection Time (minutes) indicated for each drugReported Breakthrough Detection Time (minutes) for each drug
    Cisplatin (1.0 mg/ml)> 240> 240Met Target/Passed
    Cyclophosphamide (Cytoxan) (20.0 mg/ml)> 240> 240Met Target/Passed
    Dacarbazine (10.0 mg/ml)> 240> 240Met Target/Passed
    Doxorubicin HCI (2.0 mg/ml)> 240> 240Met Target/Passed
    Etoposide (20.0 mg/ml)> 240> 240Met Target/Passed
    Fluorouracil (50.0 mg/ml)> 240> 240Met Target/Passed
    Ifosfamide (50.0 mg/ml)> 240> 240Met Target/Passed
    Methotrexate (25.0 mg/ml)> 240> 240Met Target/Passed
    Mitomycin C (0.5 mg/ml)> 240> 240Met Target/Passed
    Mitoxantrone (2.0 mg/ml)> 240> 240Met Target/Passed
    Paclitaxel (6.0 mg/ml)> 240> 240Met Target/Passed
    Vincristine Sulfate (1.0 mg/ml)> 240> 240Met Target/Passed
    Carmustine (BCNU) (3.3 mg/ml)> 240 (implied target for general safe use, but specific low time is reported)24.3Not Met (explicitly warned against use)
    ThioTepa (10.0 mg/ml)> 240 (implied target for general safe use, but specific low time is reported)48.6Not Met (explicitly warned against use)
    Fentanyl Citrate Injection (100.0 mcg/2ml)ASTM D6978> 240> 240Met Target/Passed

    Note on Cytotoxicity: The document states the cytotoxicity test "Failed" for the subject device based on the acceptance criteria of "No Cytotoxicity Reaction," as it exhibited severe cytotoxicity at higher concentrations (100% and 66% extract concentrations). However, it notes no cytotoxicity at lower concentrations (44%, 30%, 20%, 15%). The comparison table states "undiluted, 1:2 and 1:4 dilution is cytotoxicity and the dilution 1:8 and 1:16 and 1:32 us non-cytotoxic," and then concludes "Same" when comparing to the predicate device's cytotoxicity results. This implies that this level of cytotoxicity at higher concentrations is considered acceptable within the context of substantial equivalence, despite failing a generic "No Cytotoxicity Reaction" criteria. The device is still cleared, usually meaning the risk is mitigated or assessed as acceptable for the intended use.

    Note on Carmustine and ThioTepa: For Carmustine and ThioTepa, the breakthrough times are explicitly stated as "extremely low" and the warning "Do not use with Carmustine and ThioTepa" is included in the Indications for Use and the summary. This indicates these permeation times are not meeting the general acceptance criteria of > 240 minutes for safe use with chemotherapy drugs, and the device is therefore not indicated for use with these specific drugs.

    2. Sample size used for the test set and the data provenance

    The document does not specify the exact sample sizes (e.g., number of gloves, batches) used for each individual test. It lists the standards followed (e.g., ASTM D6319-10, ASTM D6124-06(2017), ASTM D5151-19, ISO 10993, ASTM D6978-2005). These standards typically define sampling plans, but the specific number of units tested is not reported in this summary.

    The data provenance is from non-clinical tests conducted by the manufacturer, Professional Latex Sdn Bhd, located in Malaysia. The tests are reported as demonstrating that the proposed device met all design specifications according to the listed standards.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    This information is not provided in the document. For medical device performance testing as described (physical, chemical, biocompatibility), "ground truth" is established by the specified test methods in the standards (e.g., ASTM for physical properties and chemical permeation, ISO for biocompatibility). These tests usually involve laboratory analysis and measurements rather than expert consensus on interpretation of, for instance, medical images. The results are objective measurements against predefined criteria.

    4. Adjudication method for the test set

    This is not applicable as the tests are primarily objective measurements against established standard criteria, not subjective interpretations requiring adjudication by experts.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    Not applicable. This document pertains to the safety and performance testing of a physical medical device (examination gloves), not an AI-powered diagnostic or assistive technology that would involve human readers or MRMC studies.

    6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

    Not applicable. This document is not about an algorithm or AI.

    7. The type of ground truth used

    The "ground truth" for the acceptance criteria is based on:

    • Standardized Test Methods and Specifications: For physical properties (e.g., length, thickness, tensile strength, elongation, powder content, freedom from holes), the ground truth is defined by the requirements of international and national standards such as ASTM D6319-10, ASTM D6124-06(2017), and ASTM D5151-19.
    • Permeation Resistance Measurement: For chemotherapy drugs and fentanyl citrate, the ground truth is the measured breakthrough detection time according to ASTM D6978-2005.
    • Biocompatibility Standards: For irritation, sensitization, cytotoxicity, and acute systemic toxicity, the ground truth is determined by the Pass/Fail criteria defined within ISO 10993 standards (ISO 10993-10, ISO 10993-5, ISO 10993-11).

    8. The sample size for the training set

    Not applicable. This device does not involve a "training set" in the context of machine learning or AI models. The testing described is for physical product validation.

    9. How the ground truth for the training set was established

    Not applicable. (See point 8).

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1